Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC By Ogkologos - July 9, 2025 857 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric or GEJ Adenocarcinoma Advancing Childhood Cancer Research: A Conversation with Dr. Brigitte Widemann Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML MOST POPULAR Tecartus Becomes First CAR T-Cell Therapy Approved for Adults with ALL November 10, 2021 New independent tobacco review sets roadmap for a smokefree England for... June 9, 2022 Mom Births Stillborn Baby But Never Anticipated Nurse’s Remark She Will... March 15, 2019 Mesothelioma Awareness Day: Spotlight on the PrE0506/DREAM3R Clinical Trial September 23, 2021 Load more HOT NEWS Extra or Missing Chromosomes May Help Cancer Cells Survive Treatment NCI Initiative Aims to Boost CAR T-Cell Therapy Clinical Trials Common anti-inflammatory drug could boost cancer immunotherapy The path to least resistance: How our researchers are outsmarting cancer’s...
